
"I am glad that taking part in a trial might help others on their own cancer journey.”
This study was looking at a drug called palifosfamide-tris alongside doxorubicin for soft tissue sarcoma.
If soft tissue sarcoma has spread into surrounding tissue or to other parts of the body, doctors usually treat it with chemotherapy. A drug they often use is called doxorubicin.
Sadly this treatment does not work for everyone. Doctors wanted to see if having a drug called palifosfamide-tris alongside doxorubicin worked better then doxorubicin alone.
Palifosfamide-tris works by sticking together the cancer cell’s DNA so that it can't come apart again. This means that the cell can't reproduce itself.
The aim of this study was to find out if doxorubicin and palifosfamide-tris together was better at treating soft tissue sarcoma that had spread than doxorubicin alone.
The trial was stopped early because results showed that people who took palifosfamide-tris weren't living without signs of their sarcoma getting worse for any longer than the people who had doxorubicin alone.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Ian Judson
National Institute for Health Research Cancer Research Network (NCRN)
Ziopharm oncology Inc
Freephone 0808 800 4040
"I am glad that taking part in a trial might help others on their own cancer journey.”